Those who have served in the military are about twice as likely to develop ALS as those who have not served.2,3
Enroll in the ALS Care Locator
MEDICAL PRACTICEREVIEW THE PIVOTAL STUDY DATA FOR RADICAVA® AND THE RESULTS FROM AN OBSERVATIONAL ANALYSIS FOR RADICAVA ORS® REVIEW NOW
Learn how veterans with ALS can get started with RADICAVA ORS® (edaravone) through the Department of Veterans Affairs (VA).
Those who have served in the military are about twice as likely to develop ALS as those who have not served.2,3
Recognizes ALS as a service-connected disease and provides medical and financial support to those with at least 90 continuous days of military service4,5,b (see footnote)
Provides resources, education, and support to caregivers of veterans6

Provides access to treatment for ALS, including RADICAVA ORS®1
Offers some benefits to a veteran's spouse or children, even if the veteran has passed away due to ALS5
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.

For unknown reasons, military veterans are more likely to be diagnosed with ALS than the general public. The addition of RADICAVA ORS® to the VA National Formulary symbolizes not only the dedication and recognition of veterans by Shionogi Inc. and the VA, but also a significant step forward for those in the ALS community in need of an alternate treatment option.
Disability compensation benefits are based on disability rating and dependent family members.9
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.
They can check with their local VHA enrollment center or military treatment facility DEERS office for more information.
My patient is not currently enrolled in the VHA healthcare system and they may still qualify for ALS treatment through the VHA.15
To get started with the VHA, they can apply16:
ONLINE at VA.gov
BY CALLING 1-877-222-VETS (1-877-222-8387)
IN PERSON at their local VA medical facility
Eligibility requirements may apply. Veterans should always contact their local VA for more information and any questions regarding their benefits coverage.
If the veteran is separating from service due to a service-connected illness, they may be eligible for VA healthcare benefits.17
Please contact your Shionogi Inc. Manager of Patient Access for more information.
aThis product is on the VA national formulary and may have prior authorization requirements that are managed at the local facility level. Contact your local VA pharmacy for additional instructions on obtaining a prior authorization for this medication. Return to content
bA service connection for ALS for any veteran who develops the disease at any time after separation from service.4 Return to content
cBased on RADICAVA ORS® prescriptions submitted in the US as of August 2025. Not independently verified. Return to content
dData on file. Shionogi Inc. Based upon data through August 31, 2025. Return to content
eFor illustrative purposes only. Return to content
DEERS=Defense Enrollment Eligibility Reporting System; MTF=Military Treatment Facility; VA=Veterans Affairs; VHA=Veterans Health Administration.
References: 1. US Department of Veterans Affairs. VA formulary advisor. Accessed May 4, 2026. https://www.va.gov/formularyadvisor/drugs/4041481-EDARAVONE-SUSP-ORAL 2. US Department of Veterans Affairs. VA improves quality of care for veterans diagnosed with ALS. News release. October 13, 2021. Accessed May 4, 2026. https://www.va.gov/opa/pressrel/pressrelease.cfm?id=5727 3. US Department of Veterans Affairs. Quality of care: ALS disease awareness month. Accessed May 4, 2026. https://www.va.gov/QUALITYOFCARE/education/ALS_Disease_Awareness_Month.asp 4. US Department of Veterans Affairs. ALS awareness month. Accessed May 4, 2026. https://www.va.gov/marion-health-care/stories/als-awareness-month 5. US Department of Veterans Affairs. Federal benefits for veterans, dependents, survivors, and caregivers. 2025; Pamphlet 80-25-1. Accessed May 4, 2026. https://department.va.gov/wp-content/uploads/2024/12/2025-Federal-Benefits-for-Veterans-Dependents-and-Survivors.pdf 6. US Department of Veterans Affairs. VA caregiver support program. Accessed May 4, 2026. https://www.caregiver.va.gov/Care_Caregivers.asp 7. Data on file. Shionogi Inc. 8. US Department of Veterans Affairs. VA makes specially adaptive housing grant eligibility automatic for veterans and servicemembers living with ALS. News release. Published March 19, 2014. Accessed May 4, 2026. https://www.va.gov/opa/pressrel/pressrelease.cfm?id=2530 9. US Department of Veterans Affairs. Current veterans disability compensation rates. Updated December 2, 2025. Accessed May 4, 2026. https://www.va.gov/disability/compensation-rates/veteran-rates 10. US Department of Veterans Affairs. Dependency and indemnity compensation. Updated May 2022. Accessed May 4, 2026. https://benefits.va.gov/BENEFITS/factsheets/survivors/dic.pdf 11. US Department of Veterans Affairs. Special claims. Updated September 19, 2025. Accessed May 4, 2026. https://www.va.gov/disability/eligibility/special-claims 12. US Department of Veterans Affairs. Automobile allowance and adaptive equipment. Updated April 14, 2025. Accessed May 4, 2026. https://www.va.gov/disability/eligibility/special-claims/automobile-allowance-adaptive-equipment 13. I Am ALS. Veteran Resources. Accessed May 4, 2026. https://www.iamals.org/get-help/veterans-resources 14. US Department of Veterans Affairs. Manage health appointments. Accessed May 4, 2026. https://www.va.gov/health-care/manage-appointments 15. US Department of Veterans Affairs. VA ALS System of Care. Veterans Health Administration. Updated February 12, 2026. Accessed June 26, 2026. https://www.va.gov/health/als.asp 16.US Department of Veterans Affairs. How to apply for VA health care. Accessed May 4, 2026. https://www.va.gov/health-care/how-to-apply 17. US Department of Veterans Affairs. Eligibility for VA health care. Accessed May 4, 2026. https://www.va.gov/health-care/eligibility
RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Shionogi Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information also available at www.radicavaors.com.
RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Shionogi Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information also available at www.radicavaors.com.
You are leaving this website, hosted by Shionogi Inc.
This link may take you to a website to which our Privacy Policy does not apply.
Shionogi Inc. does not control the content of third-party sites.